Destruction and remodeling of the extracellular matrix occurs during the formation of new blood vessels that are required for tumor growth. We sought to determine whether gene-therapy mediated in vivo delivery of tissue inhibitor of matrix metalloproteinase-3 (TIMP-3), using retroviral vector-producer cells, could suppress angiogenesis and subsequent tumor growth in a murine neuroblastoma model. Tumor volume 28 days after coinjection of tumor cells with producer cells generating TIMP-3-encoding retroviral vectors was 21% that of controls, as was the mean tumor vascular index, a measure of blood vessel maturity. When tumors were allowed to reach a mean volume of 0.05 cm 3 before treatment, their size 2 weeks later was 47% relative to controls; larger tumors were not significantly affected. When producer cells were injected at surgical sites following excision of subcutaneous tumors, local recurrence 14 days later was only 22% in TIMP-3 producer cell treated mice as compared to 71% in controls. Unsuccessful transduction of melanoma cells in situ, another tumor of neural crest origin, resulted in unimpaired tumor growth, despite the fact that these tumors are susceptible to TIMP-3 overexpression, demonstrating the importance of tumor cell transduction in this approach. Thus, retroviral vector-producer cell-mediated in vivo gene transfer of TIMP-3 to tumor cells can significantly restrict tumor-induced angiogenesis and tumor growth. This approach may be an effective adjuvant in the treatment of neuroblastoma and other solid tumors refractory to traditional therapy, although it appears to be most effective in smaller tumors or in the setting of minimal residual disease, and the tumor cells must be susceptible to retroviral vector-mediated transduction.
D
uring cancer progression activated matrix metalloproteinases (MMPs), a class of proteolytic enzymes, are involved in the degradation of the extracellular matrix (ECM), thereby permitting subsequent tumor cell invasion, neovascularization and metastasis. 1 Increased MMP activity has been demonstrated in a variety of tumors with increased aggressiveness. 2 A number of endogenous inhibitors of MMP activity exist, with the majority of MMP inhibition being mediated by a family of proteins known as tissue inhibitors of matrix metalloproteinases (TIMPs). An imbalance between MMP and TIMP activity leading to excess degradation of the ECM has been shown to be associated with a certain number of pathologic conditions, including tumor growth and metastases. [3] [4] [5] The family of TIMP molecules is a group of inhibitory proteins expressed by a variety of endogenous cells and tissues within the body. 6 ,7 TIMP-3 shows a 25% homology with its family members and is unique in that it localizes to the ECM. 8 The mechanism through which TIMP-3 mediates its effects has not been completely defined. Previous data have shown that the TIMP-3 protein can induce apoptosis in select cell lines 9, 10 and decrease tumor cell invasiveness through direct inhibition of MMP activity. 9, 10 Others have described tumor growth suppression mediated through inhibition of endothelial cell activity and subsequent inhibition of angiogenesis. 11, 12 We have shown that TIMP-3 effects are mediated through inhibition of normal capillary morphogenesis. 13 Although the exact mechanism of this tumor inhibition has not yet been fully elucidated, use of TIMP proteins as inhibitors of tumor growth is an attractive approach as an adjunct to established primary therapies.
A therapy that targets the degradation of the ECM in an attempt to prevent tumor cell invasion and tumorassociated angiogenesis will most likely be cytostatic in nature, however. Therefore, repeated administration of these agents may be required to result in effective inhibition of tumor growth. A gene therapy-mediated approach to the delivery of MMP inhibitors has a number of potential advantages: (1) Long-term expression may be achieved after a single intervention. (2) Continuous, low levels of these proteins, as would be generated from gene-modified cells, may be the optimal delivery schedule. (3) Undesirable systemic side effects may be limited by vector-mediated site-specific expression. Gene therapymediated delivery of antitumor agents after injection of retroviral-producer cells has been shown to generate prolonged local expression of these inhibitors, resulting in subsequent inhibition of tumor growth. [14] [15] [16] [17] [18] Actively dividing tumor cells can serve as the target for in vivo retroviral vector-mediated gene transfer, resulting in enforced expression of the transgene of interest. We chose to deliver TIMP-3 via an in vivo gene transfer approach, utilizing replication-deficient retroviral-producer cells, in order to study the effects on tumor growth in a murine model of neuroblastoma. Neuroblastoma is a tumor of neural crest origin and is the most common extracranial solid tumor of infants and children. Long-term survival is less than 25% for patients with ''high-risk'' disease despite a multimodal, aggressive treatment approach. Clinically, neuroblastoma can represent a challenging problem of local control because of its propensity to invade vital vascular structures, yet in preclinical models neuroblastoma has been shown to be susceptible to TIMP-3 therapy, 13 making it an appropriate tumor to study.
Materials and methods

Cell lines
The murine neuroblastoma cell line NXS2 was provided by Dr R Reisfeld (La Jolla, CA) and the murine melanoma cell line B16F10 was provided by Dr I Fidler, (Houston, TX). Each cell line was maintained in Dulbecco's modified Eagle medium (DMEM) (Mediatech, Inc., Herndon, VA) supplemented with 10% heatinactivated fetal bovine serum (Bio-Whittaker, Walkersville, MD), 100 U per ml penicillin and 100 mg per ml streptomycin (Life Technologies, Rockville, MD), and 2 mM l-glutamine (Life Technologies). GP+E86 (3T3-based ecotropic retroviral packaging cell line) (ATCC, Manassas, VA) and 293T cells (human embryonic kidney cells expressing SV40 large T antigen) (Clontech Laboratory, Palo Alto, CA) were maintained in similar media.
Retroviral vector construction
Retroviral vector plasmids based on the murine stem cell virus and encoding either TIMP-3 and green fluorescent protein (GFP) or GFP alone were constructed as previously described. 13 Briefly, cDNA for TIMP-3 (pBLAST-mTIMP-3) was obtained from InvivoGen (San Diego, CA). A 674 bp SgrAI-NheI fragment containing the TIMP-3 transgene was excised from this vector and ligated into pBlueScript (BS) (Stratagene, La Jolla, CA) cut with XmaI and XbaI to make mTimp3-BS. A 710 bp ClaI-SacII fragment from mTimp-3-BS was then ligated into MSCV-I-GFP cut with BstBI and SacII.
MSCV-I-GFP
19 is a retroviral expression plasmid that contains the MSCV LTR driving expression of enhanced GFP (Clontech). The resulting retroviral expression plasmid, MSCV-Timp-3-I-GFP, contains the GFP gene linked to an internal ribosome entry site (IRES) from encephalomyocarditis virus 20 3 0 of the mTIMP-3 cDNA.
Generation of retroviral vector-producer cell lines
GP+E86 retroviral packaging cells were transduced with conditioned medium containing high titer VSV-G (vesicular stomatitis virus)-pseudotyped MSCV-Timp-3-I-GFP or MSCV-I-GFP vector particles supplemented with 6 mg/ml polybrene (Sigma Chemical, St Louis, MO). These conditioned media were derived by cotransfection of 293T cells with the respective retroviral vector plasmids and two helper plasmids, one containing the gag and pol retroviral genes and the other containing the gene for the VSV-G envelope, as described previously. ). Finally, a model for the treatment of MRD was used in which large, established subcutaneous NXS2 tumors were excised, with subsequent injection of 1 Â 10 7 irradiated (10 Gy) producer cells (either MSCV-Timp-3-I-GFP or MSCV-I-GFP) into the surgical site at the time of skin closure. Tumor dimensions in all the three models were measured using calipers and volumes were calculated by using the following formula: tumor volume (cm 
Immunohistochemical analyses
Formalin-fixed (10%), paraffin-embedded tumor specimens were analyzed by immunohistochemistry for GFP expression, smooth muscle actin (SMA) content and endothelial cell density. Following heat-induced epitope retrieval in citrate buffer (pH ¼ 6.0, Zymed, San Francisco, CA), the following primary antibodies were used: rabbit anti-GFP (Living Colors Peptide Antibody, Palo Alto, CA) at 1:100 dilution, biotinylated monoclonal mouse anti-human smooth muscle actin (clone 1A4, DAKO, Carpinteria, CA) at 1:50 dilution, and rat antimouse CD34 (RAM34, PharMingen, San Diego, CA) at 1:100 dilution. Concentration matched rat IgG2aK (CD34), mouse IgG1K (SMA) and rabbit immunoglobulins (DAKO) were used as negative controls. The slides evaluating GFP and CD34 expression were then incubated with a secondary, biotinylated goat anti-rabbit antibody (Vector, Burlingame, CA), at 1:200 dilution and rabbit anti-rat (Vector) antibody, respectively. Following a 10-minute incubation with streptavidin-conjugated to horseradish peroxidase (DAKO), a substrate containing the chromagen DAB (3, 3 0 diaminobenzidine tetrahydrochloride) was added. All slides were counterstained with a 1:5 dilution of hematoxylin.
Endothelial cell density was determined using the method described by Weidner et al. 23 Stained tumor sections were scanned at low power and areas of greatest CD34-positive density were chosen for analysis. After identification of the ''hot spot,'' the number of individual brown staining endothelial cells or clusters was counted at Â 400. Individual tumors were also analyzed for SMA staining that was quantitated using the same method. A ''vessel maturity index'' was then determined, as defined by the number of CD34-positive endothelial cells per SMA-positive cell. 24 
TIMP-3 Western blot analysis
Protein lysates from excised tumors were made by homogenizing tumor specimens with a Dounce (Kontes, Vineland, NJ) homogenizer in 3 ml of lysis buffer ((25 mM Tris HCl, 150 mM HCl, 0.5%. NP40, 0.5% sodium deoxycholate, 0.2% SDS, 1.0 mg Pefabloc SC (Boehringer Mannheim, Indianapolis, IN), one protease inhibitor tablet (Boehringer Mannheim)) per 1.0 g of tissue. The homogenates were then incubated on ice for 30 minutes and centrifuged at 10,000 g for 10 minutes at 41C. The supernatants were then recentrifuged, collected and frozen at À701C for later use. Total protein levels were determined for each specimen using the Bradford Assay (BioRad). Equivalent amounts of total protein were electrophoresed on a 12% sodium dodecyl sulfate-polyacrylamide gel and then transferred onto polyvinyl difluoride (PVDF) membranes (Bio-Rad, Hercules, CA). TIMP
Statistical analyses
Tumor volumes are reported as means7SE. Student's ttest was used to analyze the statistical differences in endothelial cell and pericyte densities, and tumor volumes between experimental mice that received producer cells generating retroviral vectors encoding TIMP-3-I-GFP versus control mice receiving GFP-encoding producer cells. P-values less than 0.05 indicate statistical significance.
Results
Tumor prevention
In situ target cell transduction was achieved by injecting retroviral vector-producer cells at tumor sites. Producer cells were injected since this has been shown to lead to a greater degree of target cell transduction than occurs with simply injecting retroviral supernatants. 14 We have shown previously that both NXS2 and B16F10 tumor cells are highly susceptible to TIMP-3 overexpression. In vivo growth of each tumor cell line was significantly restricted by enforced, autocrine expression of TIMP-3, established following ex vivo transduction of the tumor cells with VSVG-pseudotyped retroviral vectors. 13 However, of the two cell lines, only the NXS2 cells are susceptible to transduction by the ecotropic retrovirus generated by the GP+E86-based producer cells (data not shown).
Subcutaneous neuroblastoma tumor growth in SCID mice was significantly (Po.001) inhibited when tumor cells were coinjected with irradiated MSCV-Timp-3-I-GFP retroviral-producer cells, as compared to those coinjected with MSCV-I-GFP producers. The mean tumor volume 28 days following injection (1.770.2 cm 3 , n ¼ 6) was 21% that of the GFP controls (7.970.7 cm 3 , n ¼ 6) (Fig 1a) . In addition to being smaller, the tumors were grossly less vascular with a decrease in number and caliber of ''feeder'' vessels. Successful transduction of tumor cells was confirmed by the immunohistochemical TIMP-3 restricts angiogenesis and neuroblastoma WW Spurbeck et al demonstration of GFP expression in tumors from each group (Fig 2a, b) and TIMP-3 overexpression by Western blot analysis in tumors coinjected with MSCV-Timp-3-I-GFP retroviral-producer cells (Fig 3) . Lack of GFP staining within surrounding muscle or soft tissue revealed that the vectors had selectively transduced the rapidly (Fig 2d, e) , there was a markedly lower pericyte density (SMA) in the tumors that had been coinjected with MSCV-Timp-3-I-GFP retroviral-producer cells (10.872.5 versus 2.971.8, Po.05) (Fig 2g, h ). This resulted in a 79% lower vascular maturity index for the vessels in these tumors (42 versus 9%) suggesting that these were immature, poorly functioning vessels. These results are similar to those previously observed when tumor cells were directly modified ex vivo to express high levels of TIMP-3.
Figure 1 Subcutaneous in vivo tumor growth following coinjection of tumor cells and retroviral vector-producer cells (n ¼ 6 for each group). (a) Growth of NXS2 cells coinjected with either MSCV-I-GFP (-'-) or MSCV-Timp-3-I-GFP producer cells (-K-). (b) Growth of B16F10 cells coinjected with either MSCV-I-GFP (-'-) or MSCV-Timp-3-I-GFP producer cells (-K-).
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Despite the fact that we had shown previously that, like NXS2 cells, B16F10 tumors were susceptible to enforced, autocrine expression of TIMP-3 in vivo, 13 no difference was observed between the growth of B16F10 tumors after either coinjection of MSCV-Timp-3-I-GFP retroviralproducer cells or MSCV-I-GFP controls (Fig 1b) . Immunohistochemical staining for GFP expression in B16F10 tumors from both groups confirmed that no transduction of the tumor cells with the ecotropic virus generated by the producers had occurred (data not shown) and that no intratumoral expression of TIMP-3 could be detected by Western blot analysis (Fig 3) . These results support the hypothesis that rapidly dividing tumor cells, susceptible to retroviral vector-mediated transduction, are the required target for effective retroviral vectormediated TIMP-3 gene transfer and, therefore, effective angiogenesis inhibition.
Treatment of established tumors
To evaluate the effectiveness of in vivo tumor cell transduction on the growth of established subcutaneous NXS2 tumors in SCID mice, irradiated MSCV-Timp-3-I-GFP or MSCV-I-GFP retroviral-producer cells were injected into palpable tumors of varying sizes. When tumors were allowed to reach a mean volume of 0.05 cm 3 before treatment, their size 2 weeks later was 47% smaller in the TIMP-3-treated tumors (4.070.6 cm 3 , n ¼ 8) compared to GFP controls (7.570.5 cm 3 , n ¼ 8, P ¼ .004) (Fig 4) . This occurred despite the fact that no GFP-expressing tumor cells could be identified, nor could TIMP-3 expression be detected in those tumors 2 weeks after MSCV-Timp-3-I-GFP producer cell injection (Fig  3) , suggesting that retroviral-mediated gene transfer was inefficient in this scenario. In addition, tumors from both treatment groups had similar endothelial cell densities (25.475.2 versus 28.876.6 (control tumors), P ¼ NS) and pericyte density (11.874.1 versus 12.973.8 (control tumors), P ¼ NS). A 10-fold increase in the size of established NXS2 tumors (0. 3 ) 18 days after injection, followed by the injection of irradiated retroviral-producer cells into the surgical site. Mice were then sacrificed 14 days following tumor resection. The rate of local recurrence at that time was significantly less in TIMP-3-treated mice (22%, n ¼ 9) than in GFP controls (71%, n ¼ 7) (Fig 5) . Interestingly, at the time of sacrifice, regardless of local recurrence, all mice were found to have hepatic metastases. None of the local recurrences nor the metastatic lesions had immunohistochemical evidence of GFP expression (data not shown), suggesting that local recurrence in the TIMP-3-treated mice was due, in part, to poor transduction of residual microscopic tumor in these cases and that the process of metastasis was a relatively early event in this model. Also, no difference in endothelial cell and pericyte densities was detected between the local recurrences of each treatment group (data not shown).
Discussion
Homeostasis of the ECM is a delicate balance between degradation and remodeling, the balance being maintained, in part, by the interaction of activated MMPs and specific TIMPs. Upregulation of MMP activity, favoring proteolytic degradation of the basement membrane and ECM, has been linked to tumor growth and metastasis, as well as tumor-associated angiogenesis, while inhibition of MMP activity appears to restrict these processes. We have shown previously that overexpression of TIMP-3 by ex vivo gene-modified tumor cells can inhibit the in vivo growth and angiogenesis associated with these tumor cells, and that the antiangiogenic effects of TIMP-3 appear to be mediated through the inhibition of functional capillary morphogenesis. 13 However, ultimately, ex vivo gene modification of tumor cells as part of an antiangiogenic strategy is clinically impractical. Therefore, in this study we explored the possibility of in situ tumor cell transduction.
Retroviral vector-producer cells have been used in both preclinical and clinical trials for in situ transduction. [14] [15] [16] [17] [18] Since retroviral vectors require target cell division for transgene integration, these vectors, when administered in vivo, preferentially transduce rapidly dividing cells. Previous studies have utilized producer cell-mediated gene therapy to successfully obtain in vivo gene transfer of tumor cells. [14] [15] [16] [17] [18] The target selectivity of this approach exploits the fact that the tumor cells are typically rapidly dividing, and therefore susceptible targets for replicationdefective retroviral vectors, while the relatively quiescent surrounding normal tissues are not. The retroviral vectorproducer cells themselves are injected since this has been shown to lead to a greater degree of target cell transduction than occurs with simply injecting retroviral supernatants.
14 This is probably because of continued vector production in situ leading to increased target cell exposure to the retroviral vectors.
In our experiments, we obtained efficient in vivo transduction of the tumor cells after a single injection of producer cells together with unmodified NXS2 cells. Overexpression of the TIMP-3 transgene in the resulting tumors was about 25% the level detected in tumors derived from NXS2 cells that had been transduced ex vivo with the same vector and then FACS sorted for highly transduced cells prior to tumor cell inoculation (Fig 3) . The subsequent inhibition of tumor growth and associated angiogenesis was also similar to that observed previously with ex vivo gene-modified tumor cells, with a significant decrease in the number of pericytes associated with intratumoral endothelial cells, suggesting, again, an inhibition of neovessel maturity and functional capillary morphogenesis. 13 The importance of transduction of and sustained expression from the tumor cells themselves is highlighted by two observations. First, despite the fact that B16F10 cells were previously shown to be susceptible to growth inhibition by TIMP-3, in the current study, in which an ecotropic virus was used, the B16F10 cells were not transduced and their growth, in vivo, was unperturbed. Second, no effect on tumor growth was observed when the producer cells were injected at a site remote from the tumor growth.
We investigated two additional tumor models of greater clinical relevance for anticancer therapy involving the use of these retroviral-producer cells, treating established tumors as well as surgical sites of MRD. The MSCVTimp-3-I-GFP retroviral vector-producer cells had a significant inhibitory effect on the subsequent growth of small established tumors (0.05 cm 3 ), although not as great as when the producer cells were coinjected with the tumor cells, and despite the fact that TIMP-3 could not be detected in these tumors 2 weeks after producer cell injection and no difference in pericyte density was detected by immunohistochemistry. Perhaps increased TIMP-3 expression had occurred to affect tumor growth, but below the level of detection by Western blot analysis, or perhaps the growth perturbation was achieved by transient expression of TIMP-3 protein by the producers themselves, the level of which had declined as the producer cells were eliminated. When the tumor burden TIMP-3 restricts angiogenesis and neuroblastoma WW Spurbeck et al was allowed to increase prior to producer cell administration, the effectiveness of tumor growth suppression dissipated. It is unclear, however, whether this is because of the fact that larger, older tumors have already established a mature neovasculature with pericyte covering, a process that is not reversed by TIMP-3 overexpression, or is because of the apparent poor tumor cell target transduction in the larger, established tumors. The treatment of MRD with the administration of MSCV-Timp-3-I-GFP retroviral vector-producer cells to the site of surgically excised primary tumors demonstrated a trend towards a decrease in local tumor recurrence. None of the tumors in the few mice that did suffer a recurrence demonstrated TIMP-3 or GFP expression, suggesting that treatment failure was likely because of ineffective transduction of residual disease. It is also interesting that all mice, regardless of the successful eradication of minimal local residual disease and the prevention of local recurrence, had hepatic metastases that had no evidence of retroviral vector-mediated transduction, suggesting that metastatic tumor spread was an early event in this tumor model.
In summary, these results demonstrate the potential of utilizing retroviral vector-producer cells as vehicles for the in vivo gene transfer of TIMP-3 as part of an anticancer strategy for small, but unresectable, localized tumors or in the setting of MRD. The antitumor efficacy of this strategy is dependent on successful transduction of the tumor cells for sustained inhibitor expression and appears to be mediated, at least in part, by restricting tumorassociated angiogenesis through the inhibition of functional capillary morphogenesis.
